EUVIMEDEUVIMED entdecken
Crossref

Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real‐Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS)

Bright Oworae Howardson iD, Giulia Danè iD, Luca Moroni, Marco Lanzillotta, Umberto Tanzini, Gabriele D Gallina iD, Adriana Cariddi, Biancamaria Venerandi, Lorenzo Dagna, Leone Giordano, Apostolos Karligkiotis

International Forum of Allergy & Rhinology · 2026

DOI: 10.1002/alr.70184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2026. Verfasst von Bright Oworae Howardson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing vasculitis involving upper‐ and lower‐airways. Despite biologics, sinonasal disease often persists. Evidence on ENT trajectories under anti‐IL5 treatment and role of endoscopic sinus surgery (ESS) remains limited and is often described without standardized assessment tools. This study provides a systematic, multidimensional evaluation of sinonasal outcomes under biologic therapy and analyzes the role of ESS in a real‐life cohort.

Methods

We retrospectively analyzed 52 EGPA patients with a 24‐month follow‐up on mepolizumab. Sinonasal disease was assessed by Nasal Polyp Score (NPS), Lund–Kennedy Score (LKS), Lund–Mackay score (LMK), and SNOT‐22, while systemic activity was assessed by Birmingham Vasculitis Activity Score (BVAS). Patients were stratified by mepolizumab regimen (100 mg, 300 mg, and step‐down ). Predictors of adjunctive ESS were explored through multivariate logistic regression.

Results

Systemic remission occurred in >90% of patients, with marked eosinophil suppression (median 700 → 59.5 cells/µL) and BVAS = 0. Conversely, NPS and LKS remained stable [IQR]: (NPS 4 [3–5] → 4 [2–5]; LKS 6 [4–8] → 5 [2–7.75]. Polyps persisted in 64% and mucosal edema/discharge in 92% of population. Continuous 100 mg therapy showed the greatest endoscopic improvement. Higher baseline sinonasal burden, more extensive surgical history, and mepolizumab dose variation were associated with adjunctive ESS (28.8%), whereas BVAS and eosinophils showed no correlation with ENT severity.

Conclusion

Sinonasal disease may persist despite systemic remission, suggesting a partially independent inflammatory niche. Comprehensive assessment should combine systemic markers with dedicated ENT evaluation, while management may require integrated biologic–surgical strategies in chronic structural disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsAntibodies, Monoclonal, HumanizedRhinitisSinusitisHumansFemaleMaleEndoscopyChronic DiseaseRetrospective StudiesMiddle AgedAdultAgedParanasal SinusesTreatment Outcome

Stichwörter der Autor:innen

EGPAbiologic therapyendoscopic sinus surgeryeosinophilic granulomatosis with polyangiitisnasal polyposisreal‐life study

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS San Raffaele Hospital, Milan, Italy.
  • Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
  • Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.

ORCID-Profile: Bright Oworae Howardson, Giulia Danè, Gabriele D Gallina

Zitieren

APA

Howardson, B. O., Danè, G., Moroni, L., Lanzillotta, M., Tanzini, U., Gallina, G. D., Cariddi, A., Venerandi, B., Dagna, L., Giordano, L., & Karligkiotis, A. (2026). Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real‐Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS). International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70184

Vancouver

Howardson BO, Danè G, Moroni L, Lanzillotta M, Tanzini U, Gallina GD, et al. Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real‐Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS). International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70184

BibTeX
@article{Howardson2026,
  author = {Howardson, Bright Oworae and Danè, Giulia and Moroni, Luca and Lanzillotta, Marco and Tanzini, Umberto and Gallina, Gabriele D and Cariddi, Adriana and Venerandi, Biancamaria and Dagna, Lorenzo and Giordano, Leone and Karligkiotis, Apostolos},
  title = {Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real‐Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS)},
  journal = {International Forum of Allergy & Rhinology},
  year = {2026},
  doi = {10.1002/alr.70184}
}
Kostenlos starten →